DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications
Cancer Medicine · 2025
DOI: 10.1002/cam4.70528 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Romane Muletier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Oncologie médicale, CHU Gabriel Montpied, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: DNA Methylation, Prostatic Neoplasms, Biomarkers, Tumor, Epigenesis, Genetic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background Prostate cancer is a common cancer with a variable prognosis. Its management is currently guided by histological and biological markers such as the Gleason score and PSA. Developments in molecular biology are now making it possible to identify new targets for better classification of prostate cancer. Among emerging biomarker, DNA methylation, an epigenetic process, is increasingly being studied in carcinogenesis. Techniques for analyzing DNA methylation are constantly improving, and digital PCR now allows absolute methylation quantification with high sensitivity. These techniques can be performed on circulating tumor DNA. Materials & Methods We conducted a literature review of scientific articles addressing the topic of DNA methylation in prostate cancer. Results & discussion This review summarizes the different genes whose methylation is involved in carcinogenesis and their clinical implications, both diagnostic and prognostic. Methylation monitoring could also be useful for the prediction of treatment response. However, most studies are retrospective, and prospective studies are needed to validate these data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Oncologie médicale, CHU Gabriel Montpied, Clermont-Ferrand, France.
- Hématologie Biologique, CHU Estaing, Clermont-Ferrand, France.
- Équipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.
- Service d'Urologie, CHU Gabriel Montpied, Clermont-Ferrand, France.
ORCID-Profile: Aurore Dougé
Zitieren
APA
Muletier, R., Bourgne, C., Guy, L., & Dougé, A. (2025). DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications. Cancer Medicine. https://doi.org/10.1002/cam4.70528
Vancouver
Muletier R, Bourgne C, Guy L, Dougé A. DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications. Cancer Medicine. 2025. doi:10.1002/cam4.70528
BibTeX
@article{Muletier2025,
author = {Muletier, Romane and Bourgne, Céline and Guy, Laurent and Dougé, Aurore},
title = {DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70528}
}
EUVIMED